Postprogression survival of patients with advanced hepatocellular carcinoma: Rationale for second-line trial design
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Postprogression survival of patients with advanced hepatocellular carcinoma: Rationale for second-line trial design
Authors
Keywords
-
Journal
HEPATOLOGY
Volume 58, Issue 6, Pages 2023-2031
Publisher
Wiley
Online
2013-06-20
DOI
10.1002/hep.26586
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase III trial of sunitinib (Su) versus sorafenib (So) in advanced hepatocellular carcinoma (HCC).
- (2017) A. Cheng et al. JOURNAL OF CLINICAL ONCOLOGY
- EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
- (2015) et al. JOURNAL OF HEPATOLOGY
- Correlation of progression-free and post-progression survival with overall survival in advanced colorectal cancer
- (2012) F. Petrelli et al. ANNALS OF ONCOLOGY
- Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2012) C. Verslype et al. ANNALS OF ONCOLOGY
- Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma
- (2012) Nicola Personeni et al. JOURNAL OF HEPATOLOGY
- When Progressive Disease Does Not Mean Treatment Failure: Reconsidering the Criteria for Progression
- (2012) G. R. Oxnard et al. JNCI-Journal of the National Cancer Institute
- Hepatocellular carcinoma
- (2012) Alejandro Forner et al. LANCET
- Evaluation of the mRECIST and a-Fetoprotein Ratio for Stratification of the Prognosis of Advanced-Hepatocellular-Carcinoma Patients Treated with Sorafenib
- (2012) Tomokazu Kawaoka et al. ONCOLOGY
- Management of hepatocellular carcinoma: An update
- (2011) Jordi Bruix et al. HEPATOLOGY
- The Significance of Early Alpha-Fetoprotein Level Changes in Predicting Clinical and Survival Benefits in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib
- (2011) T. Yau et al. ONCOLOGIST
- Early Decrease in α-Fetoprotein, but Not Des-γ-Carboxy Prothrombin, Predicts Sorafenib Efficacy in Patients with Advanced Hepatocellular Carcinoma
- (2011) Teiji Kuzuya et al. ONCOLOGY
- Role of Survival Post-Progression in Phase III Trials of Systemic Chemotherapy in Advanced Non-Small-Cell Lung Cancer: A Systemic Review
- (2011) Katsuyuki Hotta et al. PLoS One
- Overall Survival and Post-Progression Survival in Advanced Breast Cancer: A Review of Recent Randomized Clinical Trials
- (2010) Everardo D. Saad et al. JOURNAL OF CLINICAL ONCOLOGY
- Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
- (2010) Riccardo Lencioni et al. SEMINARS IN LIVER DISEASE
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. JNCI-Journal of the National Cancer Institute
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started